Health legislation moving through Congress would force drug makers to disclose how much they spend on continuing medical education classes for doctors, sparking some resistance from the industry.Click here to access the WSJ article (sub. req.).
For-profit continuing medical education companies have seen revenue fall by double digits in the last year, according to industry statistics, following congressional investigations into the influence of drug makers on medical research and course content.
Friday, November 13, 2009
The end of MECCs?
From the Wall Street Journal article: